Pfizer Inc. (PFE) News
Filter PFE News Items
PFE News Results
|Loading, please wait...|
PFE News Highlights
- 500 - Internal server error
- Over the past 25 days, the trend for PFE's stories per day has been choppy and unclear. It has oscillated between 1 and 14.
- The most mentioned tickers in articles about PFE are MRNA, BNTX and SA.
Latest PFE News From Around the Web
Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.
The protection from vaccinations may start to taper after several months, boosting the case for booster shots. Covid vaccine sales are looking like a long-term business for Pfizer, BioNTech, Moderna, and other producers.
The first reason Pfizer is the best of the bunch is simply that it's the leader in the coronavirus vaccine market, at least in terms of revenue. The company also said that it expects roughly $33.5 billion in sales from BNT162b2 in 2021, which is much higher than the $26 billion Pfizer had projected in its first-quarter earnings release. Moderna (NASDAQ: MRNA) is the only rival that even comes close to Pfizer, with estimated sales of $19.2 billion for its vaccine, mRNA-1273 (this estimate will, in all likelihood, be revised upward).
The clock is now ticking for a Food and Drug Administration decision on full approval for the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX). The vaccine is currently on the market in the U.S. under the FDA's Emergency Use Authorization program. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss what full FDA approval might mean for Pfizer stock.
With the Delta variant of coronavirus shaking things up, the healthcare sector has started gaining momentum.
The long-awaited turnaround for British drugmaker GlaxoSmithKline could soon be at hand, with some nudging from activist hedge fund Elliott Management.
So what will the stock market do today?
Until Novavax secures FDA approval of its Covid-19 vaccine, investors should not buy NVAX stock, which has fallen 10% in recent days.
Vaccines still offer strong protection against symptoms: over 97% of patients hospitalized for Covid these days hadn't gotten the shots.
Top U.S. infectious disease expert Dr. Anthony Fauci said on Friday he hopes regulators as soon as next month could start granting full approval for the COVID-19 vaccines, a move he said could spur unvaccinated Americans to get the shots. The Pfizer/BioNTech and Moderna two-dose vaccines and Johnson & Johnson's one-dose shot are currently being administered under emergency use authorization by the U.S. Food and Drug Administration. Full approval by the FDA could push more Americans to get the COVID-19 vaccine as it might reduce their fears about the safety of the shot and make local officials more comfortable about implementing vaccine mandates, Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to the White House, said in an intervi...
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.